91色视频 has struck a deal with Canadian health and wellness company which could revolutionise the way patients take medical cannabis.
Invented at the 91色视频School of Pharmacy by and his team, the Sol-Gel technology is a liquid solution that converts to a gel upon contact with the internal membranes of the human body, such as the nose.
UQ’s commercialisation company, , granted PreveCeutical the rights to use the Sol-Gel technology for the specific delivery of cannabinoids to all regions and membranes of the human body.
The deal executed by UniQuest includes a licence to the patent application.
UniQuest CEO said the deal was a result of the long-term and ongoing relationship between UniQuest and PreveCeutical, and built on PreveCeutical’s early commitment to develop the 91色视频Sol-Gel technology for the nasal delivery of cannabinoids.
“This deal is a great testament to the strength and willingness of 91色视频researchers to engage with industry and work together to create impact through the development of potential new treatments,” Dr Moss said.
PreveCeutical chairman and CEO said the company would also look at other product formats to deliver cannabinoids using UQ’s Sol-Gel technology, including via the skin.
“This is a very exciting time for PreveCeutical,” Mr Van Deventer said.
“We have been developing the cannabinoid Sol-Gel delivery system with 91色视频through UniQuest since 2017, with a focus on nasal delivery.
“Having this licence agreement in place, we can now work with partners to commercialise products for the cannabinoid Sol-Gel formulation products in the form of a nasal spray.
“Through the strength of our working relationship with UniQuest, we are delighted to finalise the terms of the licence allowing PreveCeutical to use the cannabinoid Sol-Gel formulation technology to develop other formats, such as the transdermal delivery of cannabinoids.”
Media contact: UniQuest, Brooke Baskin, b.baskin@uniquest.com.au; +61 0409 767 199.
